Fact Meets Function

The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.

This in vitro study examined the effects of two growth hormone secretagogues—ipamorelin and GH-releasing peptide-6—on bone mineral content in adult female rats. The researchers found that both compounds increased bone mineral content in the animal models tested. As an in vitro study, these findings represent preliminary laboratory evidence and have not yet been validated in human clinical trials.

The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. Read Post »

Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.

This human clinical study developed a pharmacokinetic-pharmacodynamic model to characterize how ipamorelin, a growth hormone-releasing peptide, is absorbed, distributed, and produces effects in the body following administration to healthy volunteers. The modeling approach integrated drug concentration measurements with observed growth hormone responses to predict the relationship between ipamorelin dose and biological effect. This research provides quantitative data on ipamorelin’s time-concentration profile and growth hormone stimulation patterns in humans (human clinical evidence level).

Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Read Post »

Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.

Researchers investigated whether ipamorelin, a growth hormone-releasing peptide, could stimulate longitudinal bone growth in a rat model. The study found that ipamorelin induced increases in longitudinal bone growth in treated rats. This evidence comes from animal model research and does not directly demonstrate effects in humans.

Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Read Post »

Ipamorelin, the first selective growth hormone secretagogue.

Ipamorelin was evaluated as a selective growth hormone secretagogue in in vitro studies, demonstrating its ability to selectively stimulate growth hormone release through specific receptor mechanisms. This in vitro research established ipamorelin’s biochemical selectivity compared to other growth hormone secretagogues available at that time. As an in vitro study, these findings demonstrate receptor-level activity but do not provide evidence regarding systemic effects or clinical outcomes in human subjects.

Ipamorelin, the first selective growth hormone secretagogue. Read Post »

[Thymic hormones. Neuroendocrine interactions and clinical use in congenital and acquired immune deficiencies].

This review examined thymic hormones and their neuroendocrine interactions in treating congenital and acquired immune deficiencies, with specific attention to TB4-Fragment. The article synthesized evidence on how thymic hormones regulate immune function through interactions with the nervous and endocrine systems, and discussed their potential clinical applications in various immunodeficiency conditions. This is a review of preclinical and clinical literature rather than original human clinical research.

[Thymic hormones. Neuroendocrine interactions and clinical use in congenital and acquired immune deficiencies]. Read Post »

Scroll to Top